Edition:
United States

Horizon Pharma PLC (HZNP.O)

HZNP.O on Nasdaq

14.37USD
24 Mar 2017
Change (% chg)

$-0.19 (-1.30%)
Prev Close
$14.56
Open
$14.51
Day's High
$14.68
Day's Low
$14.25
Volume
2,189,768
Avg. Vol
3,426,306
52-wk High
$23.44
52-wk Low
$13.05

Latest Key Developments (Source: Significant Developments)

Horizon Pharma Q4 adjusted earnings per share $0.64
Monday, 27 Feb 2017 07:00am EST 

Horizon Pharma Plc : Horizon pharma plc announces fourth-quarter and full-year 2016 financial results and provides full-year 2017 net sales and adjusted ebitda guidance . Q4 non-gaap earnings per share $0.64 . Q4 sales $310.3 million versus i/b/e/s view $309.6 million . Q4 earnings per share view $0.51 -- Thomson Reuters I/B/E/S . Sees fy 2017 sales $1.24 billion to $1.29 billion . Q4 gaap loss per share $0.81 . Sees fy 2017 sales up 19 to 23 percent .Horizon pharma plc sees full-year 2017 adjusted ebitda guidance of $525 million to $575 million.  Full Article

Horizon Pharma estimates that its cash and cash equivalents were approximately $500 mln
Tuesday, 10 Jan 2017 09:02am EST 

Horizon Pharma Plc : Estimates that its cash and cash equivalents as of December 31 were approximately $500 million . Estimates total principal amount of its indebtedness was approximately $1,945 million as of December 31 .Sees for 2016 fiscal year, net sales from its primary care medicines were approximately $600 million in aggregate.  Full Article

Horizon Pharma raises full-year 2016 net sales guidance
Tuesday, 25 Oct 2016 08:40am EDT 

Horizon Pharma Plc : Horizon Pharma plc - raises full-year 2016 net sales guidance and confirms full-year 2016 adjusted ebitda guidance . Horizon Pharma plc sees full-year 2016 net sales approximately $980 to $985 million . Horizon Pharma - raising net sales guidance on a non-GAAP adjusted basis to approximately $1.045 to $1.050 billion excluding $65 million settlement for fy .Fy2016 revenue view $1.03 billion -- Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma announces proposed private offering of senior notes
Thursday, 13 Oct 2016 07:45am EDT 

Horizon Pharma Plc : Horizon Pharma Plc announces proposed private offering of senior notes and intention to borrow incremental term loans under its existing senior secured credit facility . Horizon Pharma subsidiaries to offer $300 million aggregate principal amount of senior notes due 2024 . Horizon Pharma units to borrow $375 million aggregate principal amount of incremental term loans under Horizon's existing senior secured credit facility .Horizon Pharma expects to use net proceeds from offering and incremental term loans to fund a portion of Horizon's planned acquisition of Raptor Pharma.  Full Article

Horizon Pharma says unit enters into settlement deal with Express Scripts - SEC filing
Thursday, 29 Sep 2016 08:00am EDT 

Horizon Pharma PLC : On Sept 26, Horizon Pharma USA entered settlement agreement and mutual release with Express Scripts to settle litigation - SEC filing . 25 percent of settlement amount will be paid to Express Scripts in Q1 of 2017 and 25 percent in Q2 of 2017 . Horizon Pharma's discussions with Express Scripts regarding DUEXIS and VIMOVO on its formulary exclusion list are ongoing . Settlement amount will be paid to Express Scripts in installments, with 50 percent of installment paid in Q4 of 2016 . Expects that settlement payment will be recorded as a reduction in GAAP net sales in Q3 of fiscal 2016 .Continues its discussions and negotiations with other pharmacy benefit managers and payers.  Full Article

Horizon pharma Q2 diluted earnings per share $0.09
Monday, 8 Aug 2016 07:00am EDT 

Horizon Pharma Plc : Horizon Pharma Plc announces second-quarter 2016 financial results . Sees FY 2016 sales $1.025 billion to $1.05 billion . Q2 sales $257.4 million versus I/B/E/S view $234.9 million . Qtrly earnings per share - diluted $0.09 . Qtrly non-GAAP earnings per share - diluted $0.62 .Confirms full-year 2016 net sales guidance of $1.025 to $1.050 bln and full-year 2016 adjusted EBITDA guidance of $495 to $510 mln.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 09:01pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 03:56pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim
Thursday, 19 May 2016 07:00am EDT 

Horizon Pharma Plc : Says anticipates a reduction to 2016 adjusted ebitda of approximately $10 million versus prior guidance . Also licensed u.s., european and canadian intellectual property rights for interferon gamma-1b for treatment of friedreich's ataxia . Under terms of separate agreement with undisclosed third party, co licensed u.s., european, canadian ip rights for interferon gamma-1b . Co will immediately begin investing in related manufacturing, supply chain, regulatory,commercial activities for interferon gamma-1b . To immediately begin investing in related manufacturing, supply chain, regulatory and commercial activities for interferon gamma-1b . Paid boehringer ingelheim eur5 million upon signing, will pay eur20 million upon closing for rights for interferon gamma-1b in territories outside u.s, canada, japan .To Acquire Worldwide Rights To Interferon Gamma-1B from boehringer ingelheim international gmbh.  Full Article

Horizon Pharma says settles patent litigation with Teligent
Thursday, 12 May 2016 07:00am EDT 

Horizon Pharma Plc : Horizon Pharma Plc announces settlement of Pennsaid(r) (diclofenac sodium topical solution) 2 pct w/w patent litigation with Teligent Inc. .Says granted Teligent non-exclusive right to market a generic diclofenac sodium topical 2 pct w/w solution in United States.  Full Article

More From Around the Web